Abstract
A cell-based metabolic modifier screening platform for the discovery of modulators of convergent pyrimidine nucleotide biosynthetic pathways was designed and implemented. In screening a library of protein kinase inhibitors, multiple compounds were shown to possess previously uncharacterized nucleotide metabolism-modifying activity. The JNK inhibitor JNK-IN-8 was found to be a potent inhibitor of nucleoside transport, a property which was confirmed using nucleoside-analog Positron Emission Tomography (PET) imaging in mice. The PDK1 inhibitor OSU-03012 (also known as AR-12) and the RAF inhibitor TAK-632 were shown to inhibit the therapeutically relevant enzyme dihydroorotate dehydrogenase (DHODH) and their affinities were unambiguously confirmed through in vitro assays and co-crystallization with human DHODH.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
